INTRODUCTION {#s1}
============

Lung adenocarcinoma (LUAD), the primary histological subtype of non-small cell lung cancer (NSCLC), is the leading cause of cancer mortality both in female and male around the world \[[@R1]\].

Resection surgery is recognized as the radical treatment for patients with LUAD, However, patients frequently lose opportunity for radical resection on account of most of patients are diagnosed with advanced stage LUAD in hospitalization \[[@R2]\]. In addition, chemotherapy and radiotherapy are the standard first- and second-line treatments for patients with LUAD, but the curative effect remains undesirable \[[@R3]\]. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, greatly improve the life quality of patients, but EGFR-TKIs cannot significantly prolong overall survival and results in inevitable gefitinib-resistance \[[@R4]\]. In spite of the aforementioned advances in clinical therapy, the prognosis 5- year overall survival of patients with LUAD is dissatisfying. Although it is known that early diagnosis and treatment for patients with LUAD will be beneficial to prolong overall survival of patients, but the current diagnostic biomarker for early stage LUAD is not feasible in clinical practice on account of unsatisfactory sensitivity and specificity.

Long non-coding RNAs (lncRNAs) are those transcripts with length more than 200 nt and not translated into proteins. Mounting evidences indicate that aberrant expression of lncRNAs is involved in modulating the transcription and translation of protein-coding genes at the transcriptional level, post-transcriptional level and epigenetic level \[[@R5]\]. lncRNAs play essential roles in cell proliferation and metastasis of various cancer types. Ectopic expression of AFAP-AS1 promotes cell proliferation and inhibits cell apoptosis in esophageal squamous cell carcinoma (ESCC), which is significantly correlated with advanced TNM stage and larger tumor size \[[@R6]\]. Over-expression of lncRNA MALAT1 predicts poor recurrence-free survival in tamoxifen treated ER-positive breast cancer patients \[[@R7]\]. In gallbladder, high expression level of MALAT1 is correlated with larger tumor size, lymphatic metastasis and shorter overall survival; silencing of MALAT1 inhibits cell proliferation, cell invasion and increases cell apoptosis \[[@R8]\]. In currently, a few of articles demonstrate the lncRNA expression profiling in LUAD tissues, but the global lncRNA expression profiling in TNM I stage LUAD (stage I LUAD) is not uncovered.

In our work, lncRNA, miRNA and mRNA expression profiling of patients with early stage LUAD were obtained through RNA-sequencing, abnormally expressed lncRNAs, miRNAs and mRNAs were identified, and lncRNA/mRNA co-expression network were constructed. Our study might provide new insights into investigation of tumorigenesis mechanism in LUAD and discover of candidate diagnostic biomarkers and therapeutic targets for LUAD.

RESULTS {#s2}
=======

Differentially expressed lncRNAs and mRNAs in TNM I stage LUAD {#s2_1}
--------------------------------------------------------------

Respective 15710 lncRNAs and 22528 mRNAs were mapped with the human reference genome Ensemble GRCh38 v 84. Total of 175 differentially expressed lncRNA (DELs, 63 up- and 112 down-regulated) and 1321 differentially expressed mRNA (DEMs, 587 up- and 734 down-regulated) were identified in TNM I stage LUAD tissues compared to paired non-tumor tissues according to the threshold of *P*\<0.05 and \|log~2~Fold change\|≥1. 175 DELs and 1321 DEMs were widely distributed in all autosomes and chromosomes X ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The top 15 up- and down-regulated DELs/DEMs were shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. LOC80078 and LOC101930114 were the most significantly up- and down-regulated DELs; EEF1A2 and ANKRD1 were the most significantly up- and down-regulated DEMs in TNM I stage LUAD tissues compared to paired non-tumor tissues (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### Top 15 up- and down-regulated DELs in stage I LUAD

  lncRNAs               Chromosome   Position              log~2~FC   *P*-value
  --------------------- ------------ --------------------- ---------- -----------
  **Up-regulation**                                                   
  LOC80078              chr6         79307668-79313384     8.959      0.02875
  LOC105371855          chr17        62701313-62808381     6.49313    0.0358
  HNF1A-AS1             chr12        120969837-120972292   6.30907    0.0176
  LINC00858             chr10        84279979-84294659     5.68535    0.0238
  LOC101926969          chr2         91571574-91580863     4.86016    0.0358
  LOC442497             chr7         379424-382879         4.42594    0.0328
  LOC105374398          chr4         35981204-35985266     4.26679    0.02985
  LOC105371082          chr16        11249045-11523533     3.95453    0.0459
  RAB30-AS1             chr11        83072065-83073712     3.42599    0.0424
  CDKN2B-AS1            chr9         21967138-22121097     3.11379    0.0315
  LOC105370333          chr13        100086227-100088973   3.04753    0.04915
  LOC105374994          chr6         26813826-26827989     3.03417    0.0422
  LOC105375172          chr7         17374916-17558909     2.79503    0.00005
  LINC01106             chr2         110375108-110384843   2.73542    0.0033
  HAGLR                 chr2         176173188-176190907   2.03736    0.00005
  **Down-regulation**                                                 
  LOC101930114          chr1         209661358-209784545   -5.71679   0.0011
  LOC102724660          chr7         128434062-128469400   -5.61929   0.04095
  LOC105369761          chr12        49539040-49568225     -5.43482   0.0215
  LOC100507487          chr4         128428015-128519398   -5.00157   0.04675
  TUSC7                 chr3         116709787-116717040   -4.69494   0.0344
  LOC105378016          chr6         136557045-136793051   -4.6798    0.04305
  NR2F2-AS1             chr15        96127359-96340263     -4.62638   0.03075
  LOC101928926          chr19        19756370-19791747     -4.29708   0.0107
  LOC105371720          chr17        30236905-30292166     -4.11397   0.03245
  LOC105370818          chr15        51915876-51971801     -4.10768   0.00825
  FAM95B1               chr9         40323570-40329220     -3.95732   0.0243
  SALRNA2               chr15        70635248-70637314     -3.88695   0.0369
  LOC101930496          chr17        83110232-83119423     -3.59853   0.03035
  LOC284865             chr22        20198729-20204918     -3.58415   0.0288
  LOC105370168          chr13        39208770-39227906     -3.57939   0.0424

DELs: differentially expressed long non-coding RNAs; LUAD: lung adenocarcinoma; FDR: false discovery rate; FC: fold change; chr: chromosome.

###### Top 15 up- and down-regulated DEMs in stage I LUAD

  mRNAs                 Chromosome   Position              log~2~FC   *P*-value
  --------------------- ------------ --------------------- ---------- -----------
  **Up-regulation**                                                   
  EEF1A2                chr20        63488011-63499315     7.95929    0.0456
  CEACAM5               chr19        41708610-41730433     6.26554    0.0002
  CLDN2                 chrX         106900062-106930861   5.83291    0.00005
  HABP2                 chr10        113550830-113664070   5.77961    0.01665
  COL11A1               chr1         102876466-103108576   5.49743    0.008
  SLC9A2                chr2         102619688-102711350   5.29808    0.0217
  PTPRZ1                chr7         121873104-122062036   5.25139    0.00325
  MMP13                 chr11        102942991-102955734   5.02238    0.01595
  LOC100129940          chr12        65758019-65966291     4.97897    0.0378
  TOX3                  chr16        52436424-52547802     4.77916    0.0247
  ETV4                  chr17        43527842-43546432     4.73691    0.0109
  HS6ST2                chrX         132626009-132961395   4.63563    0.01275
  MMP7                  chr11        102520507-102530747   4.58386    0.00005
  DKK1                  chr10        52314280-52317657     4.30752    0.04615
  TMPRSS4               chr11        118015771-118125505   4.26309    0.0133
  **Down-regulation**                                                 
  ANKRD1                chr10        90912099-90921275     -7.62319   0.04905
  TRIM58                chr1         247857198-247880138   -5.23987   0.0444
  CST6                  chr11        66011990-66013505     -4.39682   0.0237
  SLC5A4                chr22        32218420-32353008     -4.2162    0.0051
  SLC6A4                chr17        30194318-30235968     -4.11118   0.00025
  MGAT5B                chr17        76850502-76950393     -3.92805   0.0085
  TMEM100               chr17        55719626-55732121     -3.91121   0.00025
  LOC105375355          chr7         76510101-76544090     -3.84847   0.03815
  ADGRE2                chr19        14689786-14778541     -3.67241   0.00015
  KIF19                 chr17        74326211-74355820     -3.50716   0.0445
  DTHD1                 chr4         36281610-36345756     -3.34849   0.037
  FCN3                  chr1         27369109-27374825     -3.32501   0.0024
  ZMYND10               chr3         50341105-50346028     -3.28484   0.0329
  BTNL9                 chr5         181040224-181061523   -3.03646   0.0001
  VIPR1                 chr3         42489298-42537573     -3.00424   0.00005

DEMs: differentially expressed mRNAs; LUAD: lung adenocarcinoma; FDR: false discovery rate; FC: fold change; chr: chromosome.

Differentially expressed miRNA (DEMIs) in stage I LUAD {#s2_2}
------------------------------------------------------

Total of 94 DEMIs including 87 up- and 7 down-regulated DEMIs were identified in TNM I stage LUAD tissues compared with paired non-tumor tissues based on the threshold of FDR\<0.001 and \|log~2~fold change\|≥1. hsa-miR-194-5p, hsa-miR-135b-5p and hsa-miR-215-3p were significantly up-regulated in stage I LUAD tissues; hsa-miR-486-5p, hsa-miR-338-3p, hsa-miR-7641, hsa-miR-138-5p, hsa-miR-451a, hsa-miR-486-3p and hsa-miR-139-3p were significantly down-regulated in early stage LUAD tissues compared with adjacent non-tumor tissues ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Construction of DEMI-DEM interaction network {#s2_3}
--------------------------------------------

The target-genes of top 15 up- and down-regulated DEMIs in stage I LUAD were predicted though miRWalk database. Those predicted target-genes were overlapped with 1321 DEMs, and DEMI-DEM interaction pairs in a negative regulation manner were our concern due to miRNA commonly negatively regulates the expression of mRNA. DEMI-DEM regulatory network were visualized by Cytoscape software. As Figure [1A](#F1){ref-type="fig"} shown, up-regulated DEMIs/down-regulated DEMs regulatory network composed of 395 nodes and 942 edges, which was involved in 15 up-regulated DEMIs and 384 DEMs; hsa-miR-182-5p, hsa-miR-200b-3p and hsa-miR-429 had the highest connectivity with down-regulated DEMs, which interacted with 99, 83 and 82 DEMs, respectively. As Figure [1B](#F1){ref-type="fig"} shown, down-regulated DEMIs/up-regulated DEMs regulatory network composed of 139 nodes and 181 edges, which was involved in 7 up-regulated DEMIs and 132 DEMs; hsa-miR-486-3p, hsa-miR-138-5p and hsa-miR-338-3p had the highest connectivity with up-regulated DEMs, which interacted with 61, 45 and 41 down-regulated DEMs, respectively.

![DEMI-DEM regulatory network in stage I lung adenocarcinoma\
**(A)** The network among up-regulated DEMIs and down-regulated DEMs. **(B)** The network among down-regulated DEMIs and up-regulated DEMs. The rectangle node and circular node indicated DEMIs and DEMs, respectively; the rose color and turquoise color represented up-regulation and down-regulation, respectively. DEMIs indicated differentially expressed microRNAs; DEMs were differentially expressed protein-coding mRNAs.](oncotarget-08-51703-g001){#F1}

The nearby DEMs of DELs in reference genome {#s2_4}
-------------------------------------------

The nearby protein-coding genes of 175 DELs with distance\<100kb were identified in GRCH38 reference genome. Total 190 nearby genes of 195 DELs were identified. Those 190 genes were overlapped with 1321 DEMs in stage I LUAD, and 42 nearby DEMs of 38 DELs were available, as Figure [2](#F2){ref-type="fig"} shown. IRF6, DIEXF and LAMB3 were the nearby DEMs of LOC101930114.

![The nearby DEMs of DELs in stage I lung adenocarcinoma\
The rectangle and circular nodes indicated DELs and DEMs, respectively; rosecolor and green color indicated up- and down-regulation, respectively. DELs indicated differentially expressed long non-coding RNAs; DEMs were differentially expressed protein-coding mRNAs.](oncotarget-08-51703-g002){#F2}

DEL/DEM co-expression network construction {#s2_5}
------------------------------------------

In order to investigate the potential functions of DELs, DEL/DEM co-expression network was constructed. PCC of each DEL-DEM co-expression pair among 175 DELs and 1321 DEMs was calculated based on the expression level of DELs/DEMs.

DEL-DEM co-expression pairs with \|PCC\>0.9\| was subjected to network construction. In Figure [3](#F3){ref-type="fig"} shown, CDKN2B-AS1, FENDRR, LINC00312, LINC00515 and LINC00162 co-expressed with 105, 63, 61, 6 and 5 DEMs, respectively.

![Co-expression network among DELs and DEMs in stage I lung adenocarcinoma\
**(A)** Sub-network of CDKN2B-AS1; **(B)** sub-network of FENDRR; **(C)** sub-network of LINC00312; **(D)** sub-network of LINC00515; **(E)** sub-network of LINC00162. Rectangle nodes and circular nodes represented DELs and DEMs, respectively. Rose color and red color indicated up-regulation; blue color and green color indicated down-regulation.](oncotarget-08-51703-g003){#F3}

DEL-DEMI-DEM network {#s2_6}
--------------------

In our study, DEL-DEMI-DEM network were constructed. As Figure [4](#F4){ref-type="fig"} shown, DEMI-DEM interaction pairs and the nearby DEMs of DELs were depicted in the network. For instance, in Figure [4](#F4){ref-type="fig"}, FOXF1 was the nearby DEM of lncRNA FENDRR and were negatively regulated by hsa-miR-200b-3p and hsa-miR-439. CDKN2B was the nearby DEM of lncRNA CDKN2B-AS1 and was negatively targeted by hsa-miR-182-5p and hsa-miR-375.

![DEL-DEMI-DEM network\
Diamond nodes and circular nodes indicated DELs and DEMs, respectively. V nodes represented DEMIs. Blue line indicated the nearby link between DEL and DEM; red line indicated the negative correlation between DEMI and DEM. Red color and turquoise color was up- and down-regulation. DELs indicated differentially expressed long non-coding RNAs; DEMs were differentially expressed protein-coding mRNAs; DEMIs indicated differentially expressed microRNAs.](oncotarget-08-51703-g004){#F4}

GO and KEGG pathway enrichment {#s2_7}
------------------------------

1321 DEMs were significantly enriched in pathways in cancer (Kegg:05200), cell adhesion molecules(Kegg:04514), focal adhesion (Kegg:04510), cytokine-cytokine receptor interaction (Kegg:04060), ECM-receptor interaction (Kegg:04512) and tight junction (Kegg:04530) (Table [3](#T3){ref-type="table"}). Furthermore, those DEMs were obviously enriched in signal transduction, cell adhesion, angiogenesis, regulation of cell proliferation, regulation of cell migration, regulation of cell apoptosis and response to hypoxia of Gene Ontology (GO) biological process (Table [3](#T3){ref-type="table"}).

###### GO biological process and KEGG signaling pathway enrichment of DEMs in stage I LUAD

  Items                                           Details                                     Support genes   FDR
  ----------------------------------------------- ------------------------------------------- --------------- ----------
  **GO-biological process enrichment (top 15)**                                                               
  GO:0007165                                      Signal transduction                         135             2.90E-29
  GO:0007155                                      Cell adhesion                               73              2.74E-18
  GO:0001525                                      Angiogenesis                                35              6.29E-15
  GO:0007275                                      Multicellular organismal development        89              1.89E-13
  GO:0008284                                      Positive regulation of cell proliferation   47              2.08E-11
  GO:0007596                                      Blood coagulation                           53              4.95E-11
  GO:0030335                                      Positive regulation of cell migration       24              1.37E-10
  GO:0001666                                      Response to hypoxia                         30              4.56E-10
  GO:0030154                                      Cell differentiation                        55              4.89E-10
  GO:0007275                                      Multicellular organismal development        44              6.01E-10
  GO:0042493                                      Response to drug                            38              5.85E-09
  GO:0043066                                      Negative regulation of apoptotic process    35              1.76E-08
  GO:0001501                                      Skeletal system development                 24              1.81E-08
  GO:0008285                                      Negative regulation of cell proliferation   39              5.06E-08
  GO:0009612                                      Response to mechanical stimulus             14              5.52E-08
  **KEGG pathway enrichment (top 15)**                                                                        
  Kegg:05200                                      Pathways in cancer                          37              2.92E-07
  Kegg:04514                                      Cell adhesion molecules (CAMs)              20              2.02E-06
  Kegg:04510                                      Focal adhesion                              26              2.30E-06
  Kegg:04060                                      Cytokine-cytokine receptor interaction      30              2.64E-06
  Kegg:04512                                      ECM-receptor interaction                    16              3.19E-06
  Kegg:04360                                      Axon guidance                               19              8.68E-06
  Kegg:04610                                      Complement and coagulation cascades         13              1.94E-05
  Kegg:04144                                      Endocytosis                                 23              2.17E-05
  Kegg:04380                                      Osteoclast differentiation                  18              2.25E-05
  Kegg:05144                                      Malaria                                     11              2.52E-05
  Kegg:04530                                      Tight junction                              18              2.76E-05
  Kegg:04666                                      Fc gamma R-mediated phagocytosis            15              2.82E-05
  Kegg:04350                                      TGF-beta signaling pathway                  14              3.09E-05
  Kegg:05219                                      Bladder cancer                              9               0.000171
  Kegg:05140                                      Leishmaniasis                               8               0.00027

GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: false discovery rate; DEMs: differentially expressed mRNAs; LUAD: lung adenocarcinoma.

qRT-PCR validation of the expression levels of dysregulatedDEMIs/DEMs in stage I LUAD {#s2_8}
-------------------------------------------------------------------------------------

qRT-PCR was subjected to validate the expression levels of dysregulated DEL/DEMI/DEM in 6 stage I LUAD tissues and 6 adjacent non-tumor tissues. 3 DELs, 5 DEMIs and 6 DEMs were used to apply for qRT-PCR verification. As Figure [5A-5E](#F5){ref-type="fig"} shown, hsa-miR-200a-3p (*P*\<0.01), hsa-miR-200b-3p (*P*\<0.05), hsa-miR-200b-5p (*P*\<0.05), hsa-miR-200c-5p (*P*\<0.05) and hsa-miR-429 (*P*\<0.01) were obviously up-regulated in stage I LUAD tissues and hsa-miR-338-3p (*P*\<0.05) was obviously down-regulated in stage I LUAD tissues compared with adjacent non-tumor tissues. The expression levels of ADARB1 (*P*\<0.01), ADRB2 (*P*\<0.05) and ANKRD1 (*P*\<0.05) were significantly down-regulated in stage I LUAD tissues; COL1A1 (*P*\<0.05) and MMP13 (*P*\<0.05) were significantly up-regulated in stage I LUAD tissues compared with adjacent non-tumor tissues (Figure [5G-5K](#F5){ref-type="fig"}).

![qRT-PCR validation of dysregulated DEMIs/DEMs in stage I LUAD compared with adjacent non-tumor tissues\
**(A)** hsa-miR-200a-3p; **(B)** hsa-miR-200b-3p; **(C)** hsa-miR-200b-5p; **(D)** hsa-miR-200c-5p; **(E)** hsa-miR-338-5p; **(F)** hsa-miR-428; **(G)** ADARB1; **(H)** ADRB2; **(I)** ANKRD1; **(J)** COL1A1; **(K)** MMP13. LUAD indicated stage I lung adenocarcinoma tissues; control indicated paired adjacent non-tumor tissues. \* represented *P*\<0.05 and \*\* represented *P* \<0.01.](oncotarget-08-51703-g005){#F5}

The expression levels of candidate DELs in LUAD were analyzed based on TCGA datasets and qRT-PCR experiments {#s2_9}
------------------------------------------------------------------------------------------------------------

The lncRNA expression profiling of LUAD tissues (case group) and adjacent non-tumor tissues (control group) were retrieved from TCGA database. In addition, the expression of 12 candidate DELs in LUAD tissues was detected through qRT-PCR methods in 6 stage I LUAD tissues and 6 adjacent non-tumor tissues. As Figure [6A](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"} shown, both of lncRNA MINCR (Figure [6A](#F6){ref-type="fig"}) and LBX2-AS1 (Figure [6E](#F6){ref-type="fig"}) weresignificantlyup-regulated in LUAD tissues based on TCGA dataset, however, thosetwo lncRNAweresignificantly down-regulated in LUAD tissues based on qRT-PCR results. In Figure [6B](#F6){ref-type="fig"}, [6C](#F6){ref-type="fig"}, [6D](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}, LINC00963 (Figure [6B](#F6){ref-type="fig"}), NR2F2-AS1 (Figure [6C](#F6){ref-type="fig"}), LINC00515 (Figure [6D](#F6){ref-type="fig"}), and LINC00162 (Figure [6F](#F6){ref-type="fig"}) were significantly down-regulated in LUAD tissues both in TCGA dataset and qRT-PCR experiment. As [Supplementary Figure 2A-2D](#SD1){ref-type="supplementary-material"} shown, LINC00312 ([Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}), MGC27382 ([Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}), LINC00472 ([Supplementary Figure 2C](#SD1){ref-type="supplementary-material"}) and FENDRR ([Supplementary Figure 2D](#SD1){ref-type="supplementary-material"}) were significantly down-regulated in LUAD tissues both inTCGA dataset and qRT-PCR experiment. CDKN2B-AS1 was significantly up-regulated in LUAD tissues based on TCGA dataset and it had the up-regulated tendency in LUAD tissues based on qRT-PCR ([Supplementary Figure 2E](#SD1){ref-type="supplementary-material"}). HNF1A-AS1 was significantly up-regulated in LUAD tissues based on TCGA dataset and had the down-regulated tendency in LUAD tissues based on qRT-PCR results ([Supplementary Figure 2F](#SD1){ref-type="supplementary-material"}).

![The cross validation of the expression levels of candidate DELs in LUAD tissues based on TCGA database and qRT-PCR experiments\
**(A)** MINCR; **(B)** LINC00963; **(C)** NR2F2-AS1; **(D)** LINC00515; **(E)** LBX2-AS1; **(F)** LINC00162. Case group and control group indicated LUAD tissues and adjacent non-tumor tissues, respectively. LUAD indicated lung adenocarcinoma tissues. \* represented *P*\<0.05 and \*\* represented *P* \<0.01.](oncotarget-08-51703-g006){#F6}

Combined with the bioinformatics analyses of our RNA-sequencing, the expression 8 of 12 candidate lncRNAs including LINC00963, NR2F2-AS1, LINC00515, LINC00162, LINC00312, MGC27382, LINC00472 and FENDRR were significantly up-regulated in LUAD tissues based on our RNA-sequencing, TCGA dataset and qRT-PCR experiment. CDKN2B-AS1 was significantly up-regulated in LUAD tissues based on our RNA-sequencing and TCGA dataset, and it had the up-regulated tendency in LUAD tissues based on qRT-PCR results. MINCR and LBX2-AS1 were significantly up-regulated in LUAD tissues both in our RNA-sequencing and TCGA dataset and those two lncRNA was significantly down-regulated in LUAD tissues based on qRT-PCR. HNF1A-AS1 was significantly down-regulated in LUAD tissues both in our RNA-sequencing and qRT-PCR, and it is significantly up-regulated in LUAD tissues based on TCGA dataset.

In summary, the expression levels of 10 of 12 DELs in LUAD through qRT-PCR experiments were compatible with our RNA-sequencing; and the expression levels of 9 of 12 DELs in LUAD tissues through qRT-PCR experiments were compatible with the TCGA dataset. In general, the results of cross validation indicated that the expression patterns of candidate DELs in LUAD based on TCGA database and qRT-PCR was compatible with our RNA-sequencing and bioinformatics analyses.

Receiver operating characteristic (ROC) curve analysis {#s2_10}
------------------------------------------------------

In order to assess the discriminatory ability of the 12 candidate DELs among LUAD tissues and adjacent non-tumor tissues generated from TCGA database, ROC curve analyses were conducted and area under the curve (AUC) were calculated. As Figure [7A-7K](#F7){ref-type="fig"} shown, the AUC of 10 DELs was more than 0.7. The AUC of CDKN2B-AS1 and HNF1A-AS1 was respective 0.563 and 0.529, less than 0.7 (Figure [7L](#F7){ref-type="fig"}, [7K](#F7){ref-type="fig"}). LINC00312, MGC27382, LINC00472 and FENDRR had the largest AUC in those 12 DELs. For LUAD diagnosis, the sensitivity and specificity of LINC00312 was 93.1% and 82.8% (Figure [7G](#F7){ref-type="fig"}); the sensitivity and specificity of MGC27382 was 96.6% and 91.8% (Figure [7H](#F7){ref-type="fig"}); the sensitivity and specificity of LINC00472 was 91.4% and 93.9% (Figure [7I](#F7){ref-type="fig"}); the sensitivity and specificity of FENDRR was 96.6% and 92.4% (Figure [7J](#F7){ref-type="fig"}); respectively.

![The discriminatory ability of DELs between LUAD tissues and adjacent non-tumor tissues was accessed with ROC curve\
**(A)** MINCR; **(B)** LINC00963; **(C)** NR2F2-AS1; **(D)** LINC00515; **(E)** LBX2-AS1; **(F)** LINC00162; **(G)** LINC00312; **(H)** MGC27382; **(I)** LINC00472; **(J)** FENDRR; **(K)** CDKN2B-AS1; **(L)** HNF1A-AS1.](oncotarget-08-51703-g007){#F7}

DISCUSSION {#s3}
==========

In our study, all of the members of miR-200 family, such as miR-200a,-3p, miR-200a-5p, miR-200b-5p, miR-200b-3p, miR-200c-5p, miR-429, miR-141-5p and miR-200c-5p were obviously up-regulated (more than 2 fold) in stage I LUAD tissues compared to adjacent non-tumor tissue, which was accordance with the previous study \[[@R9]\]. The members of miR-200 family are the powerful regulator of epithelial-to-mesenchymal transition, which is essential in cell adhesion, cell invasion and cell metastasis in non-small cell lung cancer \[[@R9]--[@R12]\]. Increased miR-429 promotes cell proliferation and cell metastasis in NSCLC \[[@R13]\]. In addition to, serum levels of miR-141, miR-200b and miR-429 are potential biomarkers for early diagnosis in lung cancer \[[@R14], [@R15]\].

Recent evidence highlights lncRNA as vital regulators of cancer biology that contribute to cancer cell functions including cell proliferation, cell apoptosis, and metastasis. In our study, total of 75 DELs were identified in stage I LUAD.

LncRNA CDKN2B-AS1 (CDKN2B antisense RNA1, also named as ANRIL), a 3.8-kb-long RNA, transcribed from the short arm of human chromosome 9 on p21.3, was significantly up-regulated in stage I LUAD tissues compared to adjacent non-tumor tissues, which was consistent with the published article \[[@R16]\]. It is reported that CDKN2B-AS1 genetic polymorphisms are significantly associated with lung cancer susceptibility and response to platinum-based chemotherapy \[[@R17]\]. CDKN2B-AS1 is increased in lung cancer plasma samples, lung cancer tissues and lung cancer cell lines compared with those samples in healthy volunteers, adjacent non-tumor tissues and normal human bronchial epithelial cells \[[@R18]\]. Higher expression of CDKN2B-AS1 is significantly correlated with higher TNM stage, larger tumor size and shorter overall survival in patients with NSCLC \[[@R16]\]. CDKN2B encodes a cyclin-dependent kinase inhibitor and functions as the regulator of cell growth. CDKN2B is the nearby DEM of CDKN2B-AS1 and was obviously down-regulated in stage I LUAD tissues compared with adjacent non-tumor tissues. Copy number loss of CDKN2B predicts poor survival in patients with lung squamous cell carcinoma \[[@R19]\]. *CDKN2B* deficiency accelerates mutant KRAS lung tumorigenesis in mice mode, which leads to cell metastasis and cell proliferation \[[@R20]\]. In the DEL-DEM network, CDKN2B-AS1 co-expressed 63 up-regulated DEMs, such as MMP13, COL11A1, COL1A1, ITGA11, VACN, THBS2 and TIMP1, which were significantly enriched in cell adhesion molecules and focal adhesion pathways and enriched in cell adhesion, response to hypoxia, signal transduction and positive regulation of cell proliferation of GO biological process. In our previous study, THBS2, COL11A1 and VACN were also identified as up-regulated genes in NSCLC compared with adjacent non-tumor tissues through integrated analysis of microarray data \[[@R21]\]. Markedly over-expression of THBS2 and its co-expressed genes (such as VCAN, CLO11A1, FAP) predicts poor survival of patients with lung cancer; down-regulation of VCAN and THBS2 inhibits cell proliferation in NSCLC \[[@R22]\]. COL11A1 and COL1A1 belong to fibrillar collagen. COL11A1 is over-expressed in NSCLC with lymph node metastasis and recurrent NSCLC tissues, which promotes cell proliferation, cell migration, cell invasion and chemo-resistance \[[@R23]\]. The biological roles of COL1A1 in LUAD are unknown. Ectopic expression of MMP13 (matrix metallopeptidase 13) predicts poorer-5-year survival in patients with NSCLC \[[@R24]\].

In the DEL-DEM co-expression network, FENDRR (also named as FOXF1-AS1)had the high connectivity with DEMs, which co-expressed with 105 DEMs. Those DEMs were significantly enriched in pathways in cancer, focal adhesion and cytokine-cytokine receptor interaction pathways; and enriched in angiogenesis, regulation of cell proliferation, cell adhesion and signal transduction of GO biological process. FENDRR is identified as one of the most aberrantly expressed lncRNAs in human Xuanwei lung cancer through microarray analysis \[[@R25]\]. A recent published article demonstrates that over-expression of FENDRR inhibits cell migration, cell invasion and mediates stem-like properties by regulating epithelia-mesenchymal transition in NSCLC \[[@R26]\]. FOXF1 was the nearby DEM of FENDRR, and it is down-regulated in stage I LUAD tissues. Up-regulated FOXF1 has anti-malignant effects of mesenchymal stem cell fusion-induced reprogramming on lung cancer cells \[[@R27]\]. In the DEL-DEMI-DEM network, FOXF1 was negatively targeted by miR-200 family members of miR-429 and miR-200b-3p. ADRB2 was one of co-expressed genes with FENDRR and it was significantly down-regulated in stage I LUAD tissues. In our previous article, ADRB2 (encodes beta-2-adrenergic receptor, a member of the G protein-coupled receptor superfamily) is also down-regulated in NSCLC tissues compared with adjacent non-tumor tissues through integrated analysis of microarray data \[[@R21]\]. Genetic variants in ADRB2 confer the risk of chronic obstructive pulmonary disease and lung adenocarcinoma \[[@R28], [@R29]\]. The roles of ADRB2 in cell behaviors of LUAD including cell proliferation, cell invasiveness and cell metastasis are unclear.

LINC00162, LINC00515 and LINC00312 were significantly down-regulated in stage I LUAD tissues compared with adjacent non-tumor tissues. LINC00162 is P38 inhibited cutaneous squamous cell carcinoma associated lincRNA, also named as PICSAR and NLC1-C. Knockdown of LINC00162 suppresses cell proliferation and cell migration by inhibiting ERK1/2 activity and down-regulating the expression of DUSP6 in cutaneous squamous cell carcinoma \[[@R30]\]. Down-regulated LINC00162 promotes cell proliferation by repressing miR-320a and miR-383in testicular embrynonal carcinoma \[[@R31]\]. ADARB1 was the nearby DEM of LINC00162 and was down-regulated in stage I LUAD tissues. The expression level of ADARB1 in lung cancer cell lines is higher than that in normal human bronchial epithelial cells;higher mRNA expression level of ADARB1 predicts a better outcome in patients with lung adenocarcinoma. In addition to, ADARB1 was co-expressed with down-regulated LINC00312 (also named as NAG7). ADARB1 was targeted by miR-200 family members of miR-183-5p and miR-141, miR-200a-3p. Over-expression of LINC00312 inhibits cell migration and cell invasion in bladder cancer through down-regulation of miR-197-3p \[[@R32]\]. Lower expression of LINC00312 predicts larger tumor size and shorter overall survival in nasopharyngeal carcinoma \[[@R33]\]. Total of 61 dysregulated DEMs were co-expressed with LINC00312 and were enriched in tight junction, cell adhesion molecules and pathways in cancer pathways, and enriched in angiogenesis, cell adhesion and signal transduction of GO biological process. The expression of LINC00515 is decreased in cisplatin-resistant cells of high-grade serous ovarian cancer \[[@R34]\]. JAM2 was the nearby DEM of LINC00515. JAM2 encodes junctional adhesion molecule 2 and belongs to the immunoglobulin superfamily. Increased methylation of *JAM2* leads to down-regulation of JAM2, which is associated with LUAD pathogenesis \[[@R35]\]. JAM2 was significantly enriched in cell adhesion molecules and tight junction. Based on aforementioned information, LINC00162, LINC00515 and LINC00312 might play essential roles in tumorigenesis of LUAD and the biological functions of those dysregulated DELs in cell proliferation, invasiveness, metastasis and angiogenesis of LUAD are needed to be explored in the future work.

The ROC curve analyses indicated that LINC00312and FENDRRmight be potential biomarkers for LUAD diagnosis. In the further work, larger cohort of LUAD patients should be enrolled and the potential value of those lncRNAs in LUAD is needed to be further validated in clinical practice.

In conclusion, we identified the aberrantly expressed lnRNAs, miRNAs and mRNAs in stage I LUAD. Our study indicated that those dysregulated genes including miR-200 family, CDKN2B-AS1, FENDRR, LINC00162, LINC00515, LINC00312, ADARB1 and JAM2might synergistically contributes to tumorigenesis in stage I LUAD based on complex interactions between each other through KEGG pathways and GO biological processes including cell adhesion molecules, focal adhesion, tight junction, pathways in cancer, cell adhesion, angiogenesis and regulation of cell proliferation and regulation of cell apoptosis.

There are limitations in our study. Firstly, novel dysregulated lncRNAs were identified, such as LINC00162, LINC00515 and LINC00312, however, the biological roles of those genes involved in LUAD were not further investigated. Secondly, the diagnostic value of identified lncRNAs and miRNAs is needed to be translated into clinical practice through large cohort of LUAD patients. Our study might pave the way for illumination of pathogenesis of LUAD and discovery of potential therapeutic targets and novel diagnosis biomarkers for LUAD patients.

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

LUAD tumor tissues and paired adjacent non-tumor tissues for RNA-sequencing were obtained from patients who underwent surgery in the Fourth Hospital of Hebei Medical University. 4 patients with TNM I stage received none of chemo- or radiotherapy before resection surgery, were enrolled into our study (from Dec 29th, 2015 to Feb 18th, 2016). The pathological type and TNM stage of patients were explicitly diagnosed by histopathology examination. The basic information of patients including gender, age and TNM stage were recorded. The details were shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. This work was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University and informed written consent was obtained from all patients. The research complied with the principles of the Declaration of Helsinki.

RNA-sequencing and data preprocessing {#s4_2}
-------------------------------------

Total RNA of collected specimens was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) for construction of cDNA libraries according to the manufacture instruction. Likewise, cDNA libraries of small RNA were constructed. Lastly, each library was conducted to IlluminaHiSeq 4000 sequencing.

The raw image data obtained from RNA-sequencing was translated into raw FASTQ sequence data. Adaptors of sequences were trimmed; nucleotides with a quality score \<20 were trimmed from the end of the sequence; N base rate of raw reads more than 10% were discarded using Cutadapt 1.9.1. For microRNA (miRNA) sequencing, sequences with length less than 18ntor more than 32nt were abnegated. TopHat was used to align the clean reads of long non-coding RNAs (lncRNAs) and protein coding mRNAs (mRNAs) with the human reference genome, Ensemble GRCh38 v 84 (hg19) \[[@R36]\]. Moreover, the alignment of miRNAs with hg19 was implemented by Bowtie. Fragments per kilobase of exon per million fragments mapped (FPKM) was used to describe the transcription abundance of lncRNAs and mRNAs, which was quantified by cuffquant and cuffnorm. miRDeep2 was used to quantified the transcription abundance of miRNAs \[[@R37]\].

Differentially expressed genes analysis {#s4_3}
---------------------------------------

The differentially expressed lncRNAs (DELs) and differentially expressed mRNA (DEMs) were identified in stage I LUAD tissues compared with adjacent non-tumor tissues by Cuffdiff. *P*\<0.05and \|log~2~fold change\|\>1 was set as the cut-off of DELs and DEMs. Differentially expressed miRNA (DEMIs) in stage I LUAD tissues were filteredusing DEGseq package in R language. miRNAs with FDR\<0.001 and \|log~2~fold change\|\>1 were selected as DEMIs.

DEL-DEM co-expression network construction {#s4_4}
------------------------------------------

Pearson correlation coefficients (PCCs) indicating co-expression relationship between DELs and DEMs were calculated. DEML-DEM co-expression pairs with \|PCC≥0.90\| were retained for network construction \[[@R38]\]. The DEL-DEM co-expression network was visualized by Cytoscape (<http://cytoscape.org/>) \[[@R39]\].

Prediction of target genes of DEMIs {#s4_5}
-----------------------------------

miRWalk database (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>), was used to predict the target-genes of DEMIs \[[@R40]\]. In our study, 6 algorithms including RNA22, miRanda, miRDB, miRWalk, PICTAR and Targetscan in miRWalk was used. Moreover, the genes, predicted by more than 4 out of 6 algorithms, were considered as the target-gene of DEMIs. The target-genes were overlapped with DEMs in stage I LUAD and DEMI-DEMs interaction pairs in a negative manner were subjected to construct network, and visualized by Cytoscape \[[@R39]\].

DEL-DEMI-DEM network {#s4_6}
--------------------

First, The nearby protein-coding genes of DELs with distance\<100kb were identified in GRCH38 reference genome. Those protein-coding genes of DELs were overlapped with DEMs and the nearby DEMs of DELs were identified. Then, the nearby DEMs of DELs were overlapped with those DEMs negatively targeted by DEMIs. Lastly, DEL-DEMI-DEM network was constructed and visualized by Cytoscape \[[@R39]\].

Gene ontology and KEGG enrichment analysis {#s4_7}
------------------------------------------

In order to understand the potential biological functions and signaling pathways of DELs in stage I LUAD, GeneCoDis3 (<http://genecodis.cnb.csic.es/analysis>) analysis were conducted to Gene Ontology (GO) biological process and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment \[[@R41]\]. Those Items with FDR\<0.05 was filtered as significant enrichments.

Quantitative real-time polymerase chain reaction (qRT-PCR) {#s4_8}
----------------------------------------------------------

Total RNA of TNM stage I LUAD tissues and adjacent non-tumor tissues were extracted by using Trizol (Invitrogen, Carlbad, CA, USA) according to the manufacture instructions. FastQuantcDNA and miRcute Plus (Tiangen, Beijing, China) and miRNA First-Strand cDNA Synthesis Kit (Tiangen, Beijing, China) was used to synthesize the cDNA of mRNA and miRNA, respectively. qRT-PCRreactions were performed by using SuperRealPreMix Plus SYBR Green Kit (Tiangen, Beijing, China) and miRcute Plus miRNAqPCR Detection Kit (Tiangen, Beijing, China) on Applied Biosystems 7500 (AppliedBiosystems, Foster City, CA, USA). GAPDH and U6 were used as internal control for mRNA and miRNA detection, respectively. The relative expression of candidate genes was calculated by using the 2^-ΔΔCT^ equation methods \[[@R42]\]. The PCR primers used in our study were shown in [Supplementary Table 3](#SD2){ref-type="supplementary-material"}. At least triple experiments were subjected to qRT-PCR verification.

The expression levels of representative lncRNAs were verified in TANRIC database {#s4_9}
--------------------------------------------------------------------------------

The Cancer Genome Atlas (TCGA, <https://tcga-data.nci.nih.gov/tcga/>) is a public funded project, which produces data at the RNA level for various cancers including lung adenocarcinom. The Atlas of Noncoding RNAs in Cancer (TANRIC, <http://ibl.mdanderson.org/tanric/_design/basic/index.html>) is an open resource for interactive exploration of lncRNAs in the context of TCGA clinical and genomic data. In our study, TANRIC database was employed to retrieve the lncRNA expression profiling of LUAD from TCGA database. The difference of expression levels of representative lncRNAs between LUAD and adjacent non-tumor tissues were calculated, which were delineated by box-plot analysis.

Receiver operating characteristic analyses {#s4_10}
------------------------------------------

In order to assess the diagnostic value of candidate DELs in LUAD, receiver operating characteristic (ROC) analyses were performed using pROC package in R language. The area under the curve (AUC) under binomial exact confidence interval was calculated to generate the ROC curve.

Statistical analysis {#s4_11}
--------------------

Mean ± standard deviation and independent-samples *t*-test was used in the statistical analysis. *P*\<0.05 was considered as significant difference. \* indicated *P*\<0.05; \*\* indicated *P*\<0.01 and \*\*\* indicated *P*\<0.001.
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